Skip to main navigation Skip to search Skip to main content

Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib

  • Koichi Azuma
  • , Tomonori Hirashima
  • , Nobuyuki Yamamoto
  • , Isamu Okamoto
  • , Toshiaki Takahashi
  • , Makoto Nishio
  • , Taizo Hirata
  • , Kaoru Kubota
  • , Kazuo Kasahara
  • , Toyoaki Hida
  • , Hiroshige Yoshioka
  • , Kaoru Nakanishi
  • , Shiro Akinaga
  • , Kazuto Nishio
  • , Tetsuya Mitsudomi
  • , Kazuhiko Nakagawa

    Research output: Contribution to journal › Article › peer-review

    33   Link opens in a new tab Citations (Scopus)

    Fingerprint

    Dive into the research topics of 'Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib'. Together they form a unique fingerprint.
    Sort by

    Pharmacology, Toxicology and Pharmaceutical Science